<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586674</url>
  </required_header>
  <id_info>
    <org_study_id>1984</org_study_id>
    <nct_id>NCT03586674</nct_id>
  </id_info>
  <brief_title>Fibrates in Pediatric Cholestasis</brief_title>
  <official_title>Fibrates: An Adjuvant Therapy for Cholestasis In Pediatric Age Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoda A. Atta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health and Population, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study conducted to assess the effect of fibrates on pruritus and biochemical picture in&#xD;
      pediatric patients with cholestatic liver diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholestatic liver disorders include a spectrum of hepatobiliary diseases of diverse&#xD;
      etiologies that are characterized by impaired hepatocellular secretion of bile, resulting in&#xD;
      accumulation of bile acids, bilirubin and cholesterol.This could result in different clinical&#xD;
      features including pruritus, malabsorption and vitamin deficiencies with subsequent&#xD;
      coagulation disorders and bone disease. Persistence of cholestasis leads to biliary fibrosis&#xD;
      which can progress to liver cirrhosis and end-stage liver disease.&#xD;
&#xD;
      Nuclear receptors (NRs) regulate ligand-activated transcription factor networks of genes for&#xD;
      the elimination and detoxification of potentially toxic biliary constituents accumulating in&#xD;
      cholestasis. Activation of several NRs also modulates fibrogenesis, inflammation, and&#xD;
      carcinogenesis as sequelae of cholestasis. Hence, It represent attractive targets for&#xD;
      pharmacotherapy of cholestatic disorders.&#xD;
&#xD;
      Several already available drugs may exert their beneficial effects in cholestasis via NR&#xD;
      activation eg, ursodeoxycholic acid via glucocorticoid receptor and pregnane X receptor, and&#xD;
      rifampicin via pregnane X receptor. Unfortunately, Some patients may not respond to these&#xD;
      medications.&#xD;
&#xD;
      Fibrates, serum Lipid lowering medication, has a stimulation action on proliferator activated&#xD;
      receptor alpha. It is a nuclear receptor with an integral role in bile homeostasis. Several&#xD;
      case reports and pilot studies have demonstrated the efficacy of fibrates in reducing serum&#xD;
      biomarkers of cholestasis and liver function abnormalities in patients with incomplete&#xD;
      response to ursodeoxycholic acid monotherapy. These results are of interest, because fibrates&#xD;
      are attracting increased attention as adjunct therapy for chronic cholestatic liver diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the pruritus grading score</measure>
    <time_frame>four months</time_frame>
    <description>The pruritus grading score includes four areas each has its score: distribution score 1-3;1= single site and 3 generalized, Severity score 1-5 ; 1= rubbing,5 = general excoriation, Frequency score 1-5; 1= episodic,5= continuous, and Sleep disturbance score 0-6 ; 0= no effect on sleep, 6= total restless.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the liver function test and lipid profile</measure>
    <time_frame>four months</time_frame>
    <description>investigate the effect on Alanine Aminotransferase (ALT),Aspartate Aminotransferase (AST) ,Albumin,Bilirubin, Bile acid, lipid profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Cholestasis</condition>
  <arm_group>
    <arm_group_label>Ursogal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipanthyl + Ursogal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipanthyl</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Lipanthyl + Ursogal</arm_group_label>
    <other_name>ursogal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursogal</intervention_name>
    <description>suspension</description>
    <arm_group_label>Lipanthyl + Ursogal</arm_group_label>
    <arm_group_label>Ursogal</arm_group_label>
    <other_name>non</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with chronic cholestatic liver disease defined as any condition in which&#xD;
             substances normally excreted into bile are retained for more than 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with anatomical or mechanical obstructive causes for cholestasis.&#xD;
&#xD;
          -  Cholestatic patients who were suffering from another liver disease.&#xD;
&#xD;
          -  Cholestatic patients who were receiving drugs affecting lipid profile.&#xD;
&#xD;
          -  Patients receiving drugs that interact with Fenofibrate (FF) e.g statins and warfarin&#xD;
&#xD;
          -  Patients with non obstructive gall bladder stones were excluded from T gp.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawhida Y Abdel Ghaffar, MD</last_name>
    <role>Study Director</role>
    <affiliation>ASU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Yassin Abdel Ghaffar Charity Center For Liver Diseases &amp; Researches</name>
      <address>
        <city>Cairo</city>
        <state>Nasr City</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National liver istitute</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048949/</url>
    <description>Review article</description>
  </link>
  <reference>
    <citation>Ghonem NS, Boyer JL. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology. 2013 May;57(5):1691-3. doi: 10.1002/hep.26155. Epub 2013 Apr 5.</citation>
    <PMID>23174993</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 14, 2018</last_update_submitted>
  <last_update_submitted_qc>July 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health and Population, Egypt</investigator_affiliation>
    <investigator_full_name>Hoda A. Atta</investigator_full_name>
    <investigator_title>Pediatric Specialist</investigator_title>
  </responsible_party>
  <keyword>pediatric cholestasis, Fibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only overall results will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

